Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2023-04-03 Regulatory Filings
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-04-03 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 29, 2023. It announces a positive End-of-Phase 2 meeting with the FDA and details about the SYNCHRONY Phase 3 clinical program for a drug. The content is primarily a regulatory disclosure of a significant event and forward-looking statements, not a full financial report or earnings release. It includes a press release as an exhibit. The document is not a full annual or quarterly report, audit report, earnings release, or other detailed financial or governance report. It is a regulatory filing reporting a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-03-29 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Akero Therapeutics, Inc. It registers additional shares under the company's 2019 Stock Option and Incentive Plan and 2019 Employee Stock Purchase Plan. The document includes legal exhibits, consents, and signatures but does not contain financial statements or performance data. Form S-8 is a registration statement for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7,564 characters) and content confirm it is not a brief announcement or a full financial report but a detailed registration statement.
2023-03-17 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement for an Open Market Sale Agreement (ATM Offering) and the termination of a previous Distribution Agreement. There are no financial statements or detailed financial performance data included, only announcements of financing activities and agreements. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is 6855 characters, sufficient for a substantive announcement rather than a brief notice. Therefore, the correct classification is CAP with high confidence.
2023-03-17 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering under a shelf registration statement. It details the terms of an at-the-market offering of common stock, including the use of proceeds, risk factors, plan of distribution, and legal matters. It is not a financial report, earnings release, or management discussion, but rather a capital raising document describing the offering and sale of securities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not just an announcement or brief notice.
2023-03-17 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 17, 2023, reporting the company's financial results for the quarter and full year ended December 31, 2022. It specifically states that a press release is furnished as an exhibit and that the information is being furnished, not filed, indicating this is an initial announcement of financial results rather than a full detailed report. The document length is 3559 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly or annual report. The key phrase 'announced its financial results' and the presence of a press release exhibit confirm this is an Earnings Release (ER).
2023-03-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.